On Tuesday, BioXcel Therapeutics Inc (NASDAQ: BTAI) was 4.07% up from the session before settling in for the closing price of $0.34. A 52-week range for BTAI has been $0.30 – $4.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 67.00% over the past five years. When this article was written, the company’s average yearly earnings per share was at 72.28%. With a float of $41.30 million, this company’s outstanding shares have now reached $42.46 million.
Let’s look at the performance matrix of the company that is accounted for 74 employees. In terms of profitability, gross margin is 4.13%, operating margin of -3295.61%, and the pretax margin is -3119.33%.
BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward BioXcel Therapeutics Inc stocks. The insider ownership of BioXcel Therapeutics Inc is 16.79%, while institutional ownership is 17.37%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.28% per share during the next fiscal year.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
You can see what BioXcel Therapeutics Inc (BTAI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.33 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ: BTAI) saw its 5-day average volume 0.71 million, a negative change from its year-to-date volume of 1.4 million. As of the previous 9 days, the stock’s Stochastic %D was 11.23%. Additionally, its Average True Range was 0.06.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 10.82%, which indicates a significant decrease from 14.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 191.14% in the past 14 days, which was higher than the 117.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4555, while its 200-day Moving Average is $1.0781. Nevertheless, the first resistance level for the watch stands at $0.3696 in the near term. At $0.3813, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.3960. If the price goes on to break the first support level at $0.3432, it is likely to go to the next support level at $0.3285. The third support level lies at $0.3168 if the price breaches the second support level.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
There are 49,629K outstanding shares of the company, which has a market capitalization of 17.77 million. As of now, sales total 1,380 K while income totals -179,050 K. Its latest quarter income was 210 K while its last quarter net income were -13,650 K.
